{"component": "contracts", "props": {"contracts": [{"intro": "", "id": "74r3KEoGX9e", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000104910705000010/eweb10k2004ex104.txt", "category_name": "Management Consulting Services Agreement", "company_name": "Easyweb Inc", "created": "March 31st, 2005", "published": true, "pretty": null, "uri": "/contracts/74r3KEoGX9e", "title": "EXHIBIT 10.4 MANAGEMENT CONSULTING SERVICES AGREEMENT BY AND BETWEEN EASYWEB, INC. AND SUMMIT FINANCIAL RELATIONS This Agreement is made as of this 10th (tenth) day of December 2004, by and between EasyWeb, Inc. (\"Company\") and Summit Financial...", "group_id": "74r3KEoGX9e", "group_samples": [{"label": "Management Consulting Services Agreement (Easyweb Inc)", "uri": "/contracts/eIxTEk5MYgM", "published": true}, {"label": "Management Consulting Services Agreement (Easyweb Inc)", "uri": "/contracts/74r3KEoGX9e", "published": true}, {"label": "Management Consulting Services Agreement (Easyweb Inc)", "uri": "/contracts/83ZSs28OjaX", "published": true}], "group_size": 3, "tags": [{"name": "Management Consulting Services Agreement", "type": "category", "uri": "/contracts/tagged/management-consulting-services-agreement"}, {"name": "Easyweb Inc", "type": "company", "uri": "/company/1107421/easyweb-inc"}, {"name": "Services-business services, nec", "type": "industry", "uri": "/contracts/tagged/services-business-services-nec"}]}, {"intro": "THIS SECURITIES ISSUANCE AGREEMENT (the \u201cAgreement\u201d), dated as of June 29, 2016, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cIssuer\u201d), and Intrexon Corporation, a Virginia corporation (\u201cIntrexon\u201d). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5. Intrexon and the Issuer may be referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "bx5aFUeKofu", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312516637464/d196354dex103.htm", "category_name": "Securities Issuance Agreement", "company_name": "Ziopharm Oncology Inc", "created": "June 30th, 2016", "published": true, "pretty": null, "uri": "/contracts/bx5aFUeKofu", "title": "SECURITIES ISSUANCE AGREEMENT", "group_id": "7E1Ed72swgf", "group_samples": [{"label": "Securities Issuance Agreement", "uri": "/contracts/7E1Ed72swgf", "published": true}, {"label": "Securities Issuance Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/bx5aFUeKofu", "published": true}, {"label": "Securities Issuance Agreement (Intrexon Corp)", "uri": "/contracts/brb4HTlcwEv", "published": true}], "group_size": 3, "tags": [{"name": "Securities Issuance Agreement", "type": "category", "uri": "/contracts/tagged/securities-issuance-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Registration Rights Agreement (this \u201cAgreement\u201d) is made and entered into as of September 9, 2009, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and the several purchasers signatory hereto (each a \u201cPurchaser\u201d and collectively, the \u201cPurchasers\u201d).", "id": "jdkPirLSTVJ", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420409048494/v160421_ex10-2.htm", "category_name": "Registration Rights Agreement", "company_name": "Ziopharm Oncology Inc", "created": "September 15th, 2009", "published": true, "pretty": null, "uri": "/contracts/jdkPirLSTVJ", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "9SAvz1wCUY3", "group_samples": [{"label": "Registration Rights Agreement (Solus Alternative Asset Management LP)", "uri": "/contracts/gVLPDlz3xHA", "published": true}, {"label": "Registration Rights Agreement (Avenue Capital Management II, L.P.)", "uri": "/contracts/9SAvz1wCUY3", "published": true}, {"label": "Registration Rights Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/jdkPirLSTVJ", "published": true}], "group_size": 3, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "EMPLOYMENT AGREEMENT (the \u201cAgreement\u201d), dated as of June 1, 2011, by and between ZIOPHARM Oncology, Inc., a Delaware corporation with principal executive offices at 1180 Avenue of the Americas, New York, NY 10036 (the \u201cCompany\u201d), and RICHARD E. BAGLEY, residing at 197 Eighth Street, #503, Charlestown, MA 02129 (the \u201cExecutive\u201d).", "id": "klu6qw4tt7U", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420411033811/v224849_ex10-1.htm", "category_name": "Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "June 3rd, 2011", "published": true, "pretty": null, "uri": "/contracts/klu6qw4tt7U", "title": "EMPLOYMENT AGREEMENT", "group_id": "baMiU2T5kyi", "group_samples": [{"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/klu6qw4tt7U", "published": true}, {"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/kf7n3HojFZz", "published": true}, {"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/baMiU2T5kyi", "published": true}], "group_size": 3, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "SUBSCRIPTION AGREEMENT (this \u201cAgreement\u201d) made as of the last date set forth on the signature page hereof between Ziopharm, Inc. (the \u201cCompany\u201d), and the undersigned (the \u201cSubscriber\u201d).", "id": "1FFOTZ9GB7i", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420405031725/v026661_ex10-7.htm", "category_name": "Subscription Agreement", "company_name": "Ziopharm Oncology Inc", "created": "October 14th, 2005", "published": true, "pretty": null, "uri": "/contracts/1FFOTZ9GB7i", "title": "SUBSCRIPTION AGREEMENT", "group_id": "1FFOTZ9GB7i", "group_samples": [{"label": "Subscription Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/1FFOTZ9GB7i", "published": true}, {"label": "Subscription Agreement (Ivory Capital Corp)", "uri": "/contracts/hWNYmFOXeWe", "published": true}], "group_size": 2, "tags": [{"name": "Subscription Agreement", "type": "category", "uri": "/contracts/tagged/subscription-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-business services, nec", "type": "industry", "uri": "/contracts/tagged/services-business-services-nec"}, {"name": "Delaware", "type": "jurisdiction", "uri": "/contracts/tagged/delaware-us"}]}, {"intro": "GERMANTOWN, Md., BOSTON, Ma., and HOUSTON, Tx., January 13, 2015 \u2013 Intrexon Corporation (NYSE: XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (NASDAQ:ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.", "id": "dCGd4o7lCT6", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312515009772/d851771dex991.htm", "category_name": "Exclusive Licensing Agreement", "company_name": "Ziopharm Oncology Inc", "created": "January 14th, 2015", "published": true, "pretty": null, "uri": "/contracts/dCGd4o7lCT6", "title": "Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact Exclusive Licensing Agreement for CAR T Cell, TCR, NK Cell Programs and Associated Technologies for the Development of Non-Viral Adoptive Cellular Therapies Combined Technologies to Leapfrog...", "group_id": "3SXSKKc1Ahv", "group_samples": [{"label": "Exclusive Licensing Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/dCGd4o7lCT6", "published": true}, {"label": "Exclusive Licensing Agreement (Intrexon Corp)", "uri": "/contracts/3SXSKKc1Ahv", "published": true}], "group_size": 2, "tags": [{"name": "Exclusive Licensing Agreement", "type": "category", "uri": "/contracts/tagged/exclusive-licensing-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}]}, {"intro": "THIS SECURITIES PURCHASE AGREEMENT (the \u201cAgreement\u201d), dated as of November 11, 2018, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a \u201cPurchaser\u201d and collectively, the \u201cPurchasers\u201d). Capitalized terms used herein but not otherwise defined shall have the meanings given to them in Section 1.5.", "id": "3XZQTNYAGAi", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312518324941/d601714dex101.htm", "category_name": "Securities Purchase Agreement", "company_name": "Ziopharm Oncology Inc", "created": "November 13th, 2018", "published": true, "pretty": null, "uri": "/contracts/3XZQTNYAGAi", "title": "SECURITIES PURCHASE AGREEMENT", "group_id": "3XZQTNYAGAi", "group_samples": [{"label": "Securities Purchase Agreement (PLx Pharma Inc.)", "uri": "/contracts/kcvMD72uCiW", "published": true}, {"label": "Securities Purchase Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/3XZQTNYAGAi", "published": true}], "group_size": 2, "tags": [{"name": "Securities Purchase Agreement", "type": "category", "uri": "/contracts/tagged/securities-purchase-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Executive Employment Agreement (the \u201cAgreement\u201d), made and entered into this 24th day of August, 2021 (the \u201cEffective Date\u201d), by and between Ziopharm Oncology, Inc. (the \u201cCompany\u201d), and Kevin S. Boyle, Sr. (\u201cExecutive\u201d).", "id": "3eEWnnp9pds", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312521260859/d11000dex101.htm", "category_name": "Executive Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "August 30th, 2021", "published": true, "pretty": null, "uri": "/contracts/3eEWnnp9pds", "title": "EXECUTIVE EMPLOYMENT AGREEMENT", "group_id": "3eEWnnp9pds", "group_samples": [{"label": "Executive Employment Agreement (BioSig Technologies, Inc.)", "uri": "/contracts/jnzYgfHN9i0", "published": true}, {"label": "Executive Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/3eEWnnp9pds", "published": true}], "group_size": 2, "tags": [{"name": "Executive Employment Agreement", "type": "category", "uri": "/contracts/tagged/executive-employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "This Separation and Release Agreement (\u201cAgreement\u201d) follows up on our recent discussions concerning the termination of your employment with Alaunos Therapeutics, Inc. (the \u201cCompany\u201d). To assist you in your transition, the Company is offering you certain transitional benefits in exchange for a mutual, general release of claims and other terms set forth below.", "id": "90FW4Pc8Xpk", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-ex10_60.htm", "category_name": "Separation and Release Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 31st, 2025", "published": true, "pretty": null, "uri": "/contracts/90FW4Pc8Xpk", "title": "December 20, 2023 Dear Kevin,", "group_id": "4fjrtdAEIf9", "group_samples": [{"label": "Separation and Release Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/90FW4Pc8Xpk", "published": true}, {"label": "Separation and Release Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/4fjrtdAEIf9", "published": true}], "group_size": 2, "tags": [{"name": "Separation and Release Agreement", "type": "category", "uri": "/contracts/tagged/separation-and-release-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "AGREEMENT (the \u201cAgreement\u201d), dated as of January 8, 2004, by and between ZYLOGEN, INC., a Delaware corporation with principal executive offices at 787 Seventh Avenue, 48th Floor, New York, NY 10019 (the \u201cCompany\u201d), and DR. JONATHAN LEWIS, residing at 1522 Fairfield Beach Road, Fairfield, CT 06824 (the \u201cExecutive\u201d).", "id": "5eRlZi10A8Y", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420405031725/v026661_ex10-2.htm", "category_name": "Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "October 14th, 2005", "published": true, "pretty": null, "uri": "/contracts/5eRlZi10A8Y", "title": "EMPLOYMENT AGREEMENT", "group_id": "5eRlZi10A8Y", "group_samples": [{"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/5eRlZi10A8Y", "published": true}, {"label": "Employment Agreement (VioQuest Pharmaceuticals)", "uri": "/contracts/1VNHqdSHwaZ", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-business services, nec", "type": "industry", "uri": "/contracts/tagged/services-business-services-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "AMENDMENT TO EMPLOYMENT AGREEMENT (the \u201cAmendment\u201d), dated as of November 23, 2020 (the \u201cEffective Date\u201d), by and between ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and Sath Shukla (the \u201cEmployee\u201d). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Employment Agreement (as defined below).", "id": "5jGTj5BoRB1", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312521063387/d20446dex1019.htm", "category_name": "Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "March 1st, 2021", "published": true, "pretty": null, "uri": "/contracts/5jGTj5BoRB1", "title": "AMENDMENT TO EMPLOYMENT AGREEMENT", "group_id": "5jGTj5BoRB1", "group_samples": [{"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/5jGTj5BoRB1", "published": true}, {"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/dEP2nesfO6X", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "THIS REGISTRATION RIGHTS AGREEMENT (this \u201cAgreement\u201d) is made and entered into as of January 13, 2015, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cIssuer\u201d), and the University of Texas System Board of Regents on behalf of The University of Texas M.D. Anderson Cancer Center, an agency of the State of Texas (\u201cMD Anderson\u201d), and shall become effective as of the Closing (as defined in the Issuance Agreement, defined below).", "id": "g2heilknCnw", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312515009772/d851771dex104.htm", "category_name": "Registration Rights Agreement", "company_name": "Ziopharm Oncology Inc", "created": "January 14th, 2015", "published": true, "pretty": null, "uri": "/contracts/g2heilknCnw", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "7uVTSSiuMEP", "group_samples": [{"label": "Registration Rights Agreement (Intrexon Corp)", "uri": "/contracts/7uVTSSiuMEP", "published": true}, {"label": "Registration Rights Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/g2heilknCnw", "published": true}], "group_size": 2, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "This Registration Rights Agreement (this \u201cAgreement\u201d) is made and entered into as of January 12, 2011, by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and Intrexon Corporation, a Virginia corporation (\u201cIntrexon\u201d).", "id": "eefyJDZJLxH", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420411011688/v212557_ex10-24.htm", "category_name": "Registration Rights Agreement", "company_name": "Ziopharm Oncology Inc", "created": "March 1st, 2011", "published": true, "pretty": null, "uri": "/contracts/eefyJDZJLxH", "title": "REGISTRATION RIGHTS AGREEMENT", "group_id": "eefyJDZJLxH", "group_samples": [{"label": "Registration Rights Agreement (Adeona Pharmaceuticals, Inc.)", "uri": "/contracts/gKN7rkgAOm3", "published": true}, {"label": "Registration Rights Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/eefyJDZJLxH", "published": true}], "group_size": 2, "tags": [{"name": "Registration Rights Agreement", "type": "category", "uri": "/contracts/tagged/registration-rights-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "We greatly value the work you do for Alaunos, and we need you to continue making your valuable contributions. As an incentive for you to stay with Alaunos during this period of transition, Alaunos is pleased to offer you a retention bonus (the \u201cRetention Bonus\u201d) pursuant to and in accordance with this Confidential Retention Agreement (this \u201cAgreement\u201d).", "id": "goXNbWiHbIP", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017023063354/tcrt-ex10_1.htm", "category_name": "Confidential Retention Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "November 14th, 2023", "published": true, "pretty": null, "uri": "/contracts/goXNbWiHbIP", "title": "CONFIDENTIAL", "group_id": "goXNbWiHbIP", "group_samples": [{"label": "Confidential Retention Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/goXNbWiHbIP", "published": true}, {"label": "Confidential Retention Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/ihl1AtDHZaP", "published": true}], "group_size": 2, "tags": [{"name": "Confidential Retention Agreement", "type": "category", "uri": "/contracts/tagged/confidential-retention-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "This Consulting Agreement (this \u201cAgreement\u201d), dated as of November 14, 2023, is made by and between Alaunos Therapeutics, Inc. (the \u201cCompany\u201d) and Melinda Lackey (\u201cConsultant\u201d), (together the \u201cParties\u201d).", "id": "gvvRIlcEuAU", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-ex10_59.htm", "category_name": "Consulting Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 31st, 2025", "published": true, "pretty": null, "uri": "/contracts/gvvRIlcEuAU", "title": "CONSULTING AGREEMENT", "group_id": "gvvRIlcEuAU", "group_samples": [{"label": "Consulting Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/gvvRIlcEuAU", "published": true}, {"label": "Consulting Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/lWUwO6fJpTi", "published": true}], "group_size": 2, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This LICENSE AGREEMENT (\u201cAGREEMENT\u201d) is made on this 13th day of January, 2015, by and among THE BOARD OF REGENTS (\u201cBOARD\u201d) of THE UNIVERSITY OF TEXAS SYSTEM (\u201cSYSTEM\u201d), an agency of the State of Texas, on behalf of THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (\u201cUTMDACC\u201d), a member institution of SYSTEM, and ZIOPHARM ONCOLOGY, INC., a Delaware corporation (\u201cZIOPHARM\u201d), and INTREXON CORPORATION, a Virginia corporation (\u201cINTREXON\u201d). ZIOPHARM and INTREXON are referenced herein collectively as the \u201cLICENSEE\u201d and shall each be liable and responsible, jointly and severally, for all obligations, covenants, agreements, and promises of LICENSEE as set forth herein.", "id": "ko0Ynt9xbdz", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312515023826/d862579dex105.htm", "category_name": "License Agreement", "company_name": "Ziopharm Oncology Inc", "created": "January 28th, 2015", "published": true, "pretty": null, "uri": "/contracts/ko0Ynt9xbdz", "title": "LICENSE AGREEMENT", "group_id": "idNQeKe5nY", "group_samples": [{"label": "License Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/ko0Ynt9xbdz", "published": true}, {"label": "License Agreement (Intrexon Corp)", "uri": "/contracts/idNQeKe5nY", "published": true}], "group_size": 2, "tags": [{"name": "License Agreement", "type": "category", "uri": "/contracts/tagged/license-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "This Consulting Agreement (this \u201cAgreement\u201d), dated as of December 22, 2023, is made by and between Alaunos Therapeutics, Inc. (the \u201cCompany\u201d) and Kevin S. Boyle Sr. (\u201cConsultant\u201d).", "id": "iiIGofCzzRh", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-ex10_61.htm", "category_name": "Consulting Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 31st, 2025", "published": true, "pretty": null, "uri": "/contracts/iiIGofCzzRh", "title": "CONSULTING AGREEMENT", "group_id": "iiIGofCzzRh", "group_samples": [{"label": "Consulting Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/iiIGofCzzRh", "published": true}, {"label": "Consulting Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/lKyF0v9Pxlp", "published": true}], "group_size": 2, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "AGREEMENT (the \u201cAgreement\u201d), dated as of January 15, 2004, by and between ZIOPHARM, INC., a Delaware corporation with principal executive offices at 787 Seventh Avenue, 48th Floor, New York, NY 10019 (the \u201cCompany\u201d), and ROBERT PETER GALE, M.D., Ph.D., residing at 11693 San Vicente Blvd., Suite 335, Los Angeles, CA 90049 (the \u201cEmployee\u201d).", "id": "jb0OVuOCj2E", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420405031725/v026661_ex10-3.htm", "category_name": "Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "October 14th, 2005", "published": true, "pretty": null, "uri": "/contracts/jb0OVuOCj2E", "title": "EMPLOYMENT AGREEMENT", "group_id": "jb0OVuOCj2E", "group_samples": [{"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/kj4lMDOS9Sc", "published": true}, {"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/jb0OVuOCj2E", "published": true}], "group_size": 2, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-business services, nec", "type": "industry", "uri": "/contracts/tagged/services-business-services-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Consulting Agreement (this \u201cAgreement\u201d), dated as of February 22, 2024, is made by and between Alaunos Therapeutics, Inc. (the \u201cCompany\u201d) and Ferdinand Groenewald (\u201cConsultant\u201d), (together the \u201cParties\u201d).", "id": "kgrlNoUbSQT", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017025047758/tcrt-ex10_62.htm", "category_name": "Consulting Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 31st, 2025", "published": true, "pretty": null, "uri": "/contracts/kgrlNoUbSQT", "title": "CONSULTING AGREEMENT", "group_id": "joooXmmYYqC", "group_samples": [{"label": "Consulting Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/kgrlNoUbSQT", "published": true}, {"label": "Consulting Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/joooXmmYYqC", "published": true}], "group_size": 2, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This Amendment, dated as of February 1, 2011 (this \u201cAmendment\u201d), to the Stock Purchase Agreement, dated as of January 6, 2011 (the \u201cPurchase Agreement\u201d), by and between ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and Intrexon Corporation, a Virginia corporation (\u201cIntrexon\u201d). Capitalized terms used in this Amendment and not otherwise defined shall have the respective meanings ascribed to such terms in the Purchase Agreement.", "id": "1G62ekJqigq", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420411006288/v210222_ex10-1.htm", "category_name": "Stock Purchase Agreement", "company_name": "Ziopharm Oncology Inc", "created": "February 7th, 2011", "published": true, "pretty": null, "uri": "/contracts/1G62ekJqigq", "title": "AMENDMENT TO STOCK PURCHASE AGREEMENT", "group_id": "1G62ekJqigq", "group_samples": [{"label": "Stock Purchase Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/1G62ekJqigq", "published": true}], "group_size": 1, "tags": [{"name": "Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/stock-purchase-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This is the fifth amendment (\u201cFifth Amendment\u201d) of the agreement by and between the IC and Licensee having an effective date of May 28, 2019 and having IC Reference Number L-190-2019-0 (\u201cAgreement\u201d). This Fifth Amendment, having IC Reference Number L-190-2019-5 includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Royalty Payment Information), and 3) Appendix A - Patent(s) or Patent Application(s).", "id": "1dPRvtNbLpz", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_40.htm", "category_name": "Amendment", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 30th, 2022", "published": true, "pretty": null, "uri": "/contracts/1dPRvtNbLpz", "title": "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ALAUNOS THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE. PUBLIC HEALTH...", "group_id": "1dPRvtNbLpz", "group_samples": [{"label": "Amendment (Alaunos Therapeutics, Inc.)", "uri": "/contracts/1dPRvtNbLpz", "published": true}], "group_size": 1, "tags": [{"name": "Amendment", "type": "category", "uri": "/contracts/tagged/amendment"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "Such counsel has acted as counsel to the Company in connection with the preparation of the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, and each amendment or supplement thereto made by the Company prior to the Closing Date. Based on (x) such counsel\u2019s examination of the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, and each amendment or supplement thereto made by the Company prior to the Closing Date and the documents incorporated by reference in the Time of Sale Disclosure Package or the Prospectus and any further amendment or supplement to any such incorporated document made by the Company prior to the Closing Date and (y) such counsel\u2019s investigation made in connection with the preparation of the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, and each amendment or supplement thereto made by the Company prior to the Closing Date and discussions with representatives of the Underwriter", "id": "1h3CNAajdeg", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420409063578/v168411_ex1-1.htm", "category_name": "Underwriting Agreement", "company_name": "Ziopharm Oncology Inc", "created": "December 8th, 2009", "published": true, "pretty": null, "uri": "/contracts/1h3CNAajdeg", "title": "15,484,000 Shares Warrants to Purchase 7,742,000 Shares ZIOPHARM Oncology, Inc. Common Stock ($0.001 par value) UNDERWRITING AGREEMENT", "group_id": "1h3CNAajdeg", "group_samples": [{"label": "Underwriting Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/1h3CNAajdeg", "published": true}], "group_size": 1, "tags": [{"name": "Underwriting Agreement", "type": "category", "uri": "/contracts/tagged/underwriting-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "THIS CONSULTING AGREEMENT (the \u201cAgreement\u201d), made this 26th day of May, 2020 (the \u201cSeparation Date\u201d), is entered into by Ziopharm Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and David Mauney, M.D. (the \u201cConsultant\u201d).", "id": "1uoxMoCl0RP", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312520155032/d863863dex101.htm", "category_name": "Consulting Agreement", "company_name": "Ziopharm Oncology Inc", "created": "May 29th, 2020", "published": true, "pretty": null, "uri": "/contracts/1uoxMoCl0RP", "title": "CONSULTING AGREEMENT", "group_id": "1uoxMoCl0RP", "group_samples": [{"label": "Consulting Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/1uoxMoCl0RP", "published": true}], "group_size": 1, "tags": [{"name": "Consulting Agreement", "type": "category", "uri": "/contracts/tagged/consulting-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "THIS AMENDMENT TO EMPLOYMENT AGREEMENT (the \u201cAmendment\u201d) is entered into and effective on January 7, 2014 (the \u201cEffective Date\u201d), and as of the Effective Date amends the Employment Agreement dated September 6, 2011 by and between ZIOPHARM ONCOLOGY, INC. (hereinafter the \u201cCompany\u201d), and Caesar J. Belbel (hereinafter \u201cExecutive\u201d), (the \u201cEmployment Agreement\u201d).", "id": "203dygZImVX", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312514005438/d655985dex102.htm", "category_name": "Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "January 8th, 2014", "published": true, "pretty": null, "uri": "/contracts/203dygZImVX", "title": "AMENDMENT TO EMPLOYMENT AGREEMENT", "group_id": "203dygZImVX", "group_samples": [{"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/203dygZImVX", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This AMENDMENT #2 (\u201cAMENDMENT #2\u201d) to the RESEARCH AND DEVELOPMENT AGREEMENT (the \u201cAGREEMENT\u201d) is entered into as of January 17, 2017 by and among THE UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER (\u201cUTMDACC\u201d), INTREXON CORPORATION (\u201cINTREXON\u201d) and ZIOPHARM ONCOLOGY, INC. (\u201cZIOPHARM\u201d). Capitalized terms used herein and not defined shall have the meaning ascribed to them in the AGREEMENT.", "id": "2CzIioJC60r", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312519063978/d678734dex1022.htm", "category_name": "Research and Development Agreement", "company_name": "Ziopharm Oncology Inc", "created": "March 5th, 2019", "published": true, "pretty": null, "uri": "/contracts/2CzIioJC60r", "title": "AMENDMENT #2 TO THE RESEARCH AND DEVELOPMENT AGREEMENT", "group_id": "2CzIioJC60r", "group_samples": [{"label": "Research and Development Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/2CzIioJC60r", "published": true}], "group_size": 1, "tags": [{"name": "Research and Development Agreement", "type": "category", "uri": "/contracts/tagged/research-and-development-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "AMENDMENT TO EMPLOYMENT AGREEMENT (the \u201cAmendment\u201d), dated as of November 23, 2020 (the \u201cEffective Date\u201d), by and between ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and Jill Buck (the \u201cEmployee\u201d). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Employment Agreement (as defined below).", "id": "2J533dwjalc", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_18.htm", "category_name": "Employment Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 30th, 2022", "published": true, "pretty": null, "uri": "/contracts/2J533dwjalc", "title": "AMENDMENT TO EMPLOYMENT AGREEMENT", "group_id": "2J533dwjalc", "group_samples": [{"label": "Employment Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/2J533dwjalc", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Agreement (\u201cAgreement\u201d) is made and entered into as of January 6, 2011 (the \u201cEffective Date\u201d), by and among ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and Intrexon Corporation, a Virginia corporation (\u201cIntrexon\u201d).", "id": "2TndKq08K5m", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420411001806/v207772_ex10-2.htm", "category_name": "Stock Purchase Agreement", "company_name": "Ziopharm Oncology Inc", "created": "January 12th, 2011", "published": true, "pretty": null, "uri": "/contracts/2TndKq08K5m", "title": "STOCK PURCHASE AGREEMENT", "group_id": "2TndKq08K5m", "group_samples": [{"label": "Stock Purchase Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/2TndKq08K5m", "published": true}], "group_size": 1, "tags": [{"name": "Stock Purchase Agreement", "type": "category", "uri": "/contracts/tagged/stock-purchase-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This is the second amendment (\u201cSecond Amendment\u201d) of the agreement by and between the IC and Licensee having an effective date of May 28, 2019 and having IC Reference Number L-190-2019/0 (\u201cAgreement\u201d). This Second Amendment, having IC Reference Number L-190-2019/2 includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Royalty Payment Information), and 3) Appendix A - Patent(s) or Patent Application(s).", "id": "2jXBXJgQYpk", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312520286807/d82436dex101.htm", "category_name": "Amendment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "November 5th, 2020", "published": true, "pretty": null, "uri": "/contracts/2jXBXJgQYpk", "title": "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ZIOPHARM ONCOLOGY, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZIOPHARM ONCOLOGY, INC....", "group_id": "2jXBXJgQYpk", "group_samples": [{"label": "Amendment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/2jXBXJgQYpk", "published": true}], "group_size": 1, "tags": [{"name": "Amendment Agreement", "type": "category", "uri": "/contracts/tagged/amendment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}, {"intro": "This letter (this \u201cAgreement\u201d) constitutes the agreement between Alaunos Therapeutics, Inc., a Delaware corporation (the \u201cCompany\u201d), and Dawson James Securities, Inc. (\u201cDawson\u201d) pursuant to which Dawson shall serve as the placement agent (the \u201cPlacement Agent\u201d) (the \u201cServices\u201d), for the Company, on a reasonable \u201cbest efforts\u201d basis, in connection with the proposed offer and placement (the \u201cOffering\u201d) by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson\u2019s obligations hereunder are on a reasonable \u201cbest efforts\u201d basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities. The terms of the Offering and the Securities shall be mutually agreed upon by the Company and the Purchasers and nothing herein grants the Placemen", "id": "38Ie07PbfGH", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312526397996/tcrt-ex10_2.htm", "category_name": "Placement Agency Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "September 22nd, 2026", "published": true, "pretty": null, "uri": "/contracts/38Ie07PbfGH", "title": "PLACEMENT AGENCY AGREEMENT", "group_id": "38Ie07PbfGH", "group_samples": [{"label": "Placement Agency Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/38Ie07PbfGH", "published": true}], "group_size": 1, "tags": [{"name": "Placement Agency Agreement", "type": "category", "uri": "/contracts/tagged/placement-agency-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Fifth Amendment to Research and Development Agreement (this \u201cFifth Amendment\u201d) is made as of October 22, 2019 (the \u201cFifth Amendment Effective Date\u201d), by and among THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER (\u201cUTMDACC\u201d), a member institution of THE UNIVERSITY OF TEXAS SYSTEM (\u201cSYSTEM\u201d), and ZIOPHARM ONCOLOGY, INC., a Delaware corporation (\u201cZIOPHARM\u201d).", "id": "3AtleTUoEAU", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000119312520058863/d861766dex1020.htm", "category_name": "Research and Development Agreement", "company_name": "Ziopharm Oncology Inc", "created": "March 2nd, 2020", "published": true, "pretty": null, "uri": "/contracts/3AtleTUoEAU", "title": "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*****], HAS BEEN OMITTED BECAUSE ZIOPHARM ONCOLOGY, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO ZIOPHARM ONCOLOGY, INC....", "group_id": "3AtleTUoEAU", "group_samples": [{"label": "Research and Development Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/3AtleTUoEAU", "published": true}], "group_size": 1, "tags": [{"name": "Research and Development Agreement", "type": "category", "uri": "/contracts/tagged/research-and-development-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "This Employment Agreement (this \u201cAgreement\u201d) is made and entered into as of November 29, 2021 (the \u201cEffective Date\u201d), notwithstanding that this Agreement may be executed on a different date, by and between Ziopharm Oncology, Inc. (the \u201cCompany\u201d), and Melinda K. Lackey (\u201cExecutive\u201d). Each of the Company and Executive are referred to herein individually as a \u201cParty\u201d and collectively as the \u201cParties.\u201d", "id": "3DFgRadgQ23", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017023020088/tcrt-ex10_4.htm", "category_name": "Employment Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "May 10th, 2023", "published": true, "pretty": null, "uri": "/contracts/3DFgRadgQ23", "title": "EMPLOYMENT AGREEMENT", "group_id": "3DFgRadgQ23", "group_samples": [{"label": "Employment Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/3DFgRadgQ23", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Texas", "type": "jurisdiction", "uri": "/contracts/tagged/texas-us"}]}, {"intro": "AMENDMENT TO EMPLOYMENT AGREEMENT (the \u201cAmendment\u201d), dated as of November 23, 2020 (the \u201cEffective Date\u201d), by and between ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and Eleanor De Groot (the \u201cEmployee\u201d). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Employment Agreement (as defined below).", "id": "3GpWXDnIuOz", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_20.htm", "category_name": "Employment Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 30th, 2022", "published": true, "pretty": null, "uri": "/contracts/3GpWXDnIuOz", "title": "AMENDMENT TO EMPLOYMENT AGREEMENT", "group_id": "3GpWXDnIuOz", "group_samples": [{"label": "Employment Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/3GpWXDnIuOz", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}, {"name": "Massachusetts", "type": "jurisdiction", "uri": "/contracts/tagged/massachusetts-us"}]}, {"intro": "This Agreement and Plan of Merger (this \u201cAgreement\u201d) is entered into as of August 3, 2005, by and among EasyWeb, Inc., a Delaware corporation having a place of business located at 6025 S. Quebec Street, Suite 135, Englewood, Colorado (\u201cEasyWeb\u201d), ZIOPHARM, Inc., a Delaware corporation having a place of business located at Suite 1920, 1180 Avenue of the Americas, New York, New York (\u201cZIOPHARM\u201d), and ZIO Acquisition Corp., a Delaware corporation having a place of business located at 6025 S. Quebec Street, Suite 135, Englewood, Colorado (\u201cZAC\u201d).", "id": "3Lj76QsUG34", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000112178105000194/exhibit10one.htm", "category_name": "Merger Agreement", "company_name": "Easyweb Inc", "created": "August 9th, 2005", "published": true, "pretty": null, "uri": "/contracts/3Lj76QsUG34", "title": "AGREEMENT AND PLAN OF MERGER", "group_id": "3Lj76QsUG34", "group_samples": [{"label": "Merger Agreement (Easyweb Inc)", "uri": "/contracts/3Lj76QsUG34", "published": true}], "group_size": 1, "tags": [{"name": "Merger Agreement", "type": "category", "uri": "/contracts/tagged/merger-agreement"}, {"name": "Easyweb Inc", "type": "company", "uri": "/company/1107421/easyweb-inc"}, {"name": "Services-business services, nec", "type": "industry", "uri": "/contracts/tagged/services-business-services-nec"}, {"name": "New York", "type": "jurisdiction", "uri": "/contracts/tagged/new-york-us"}]}, {"intro": "Reference is made to the Employment Agreement (the \u201cAgreement\u201d), dated as of July 21, 2004, by and between Ziopharm, Inc., a Delaware corporation and the predecessor to ZIOPHARM Oncology, Inc., a Delaware corporation (the \u201cCompany\u201d), and RICHARD BAGLEY (the \u201cEmployee\u201d). All terms used, but not otherwise defined herein, shall have the meanings assigned to them in the Agreement.", "id": "3WaxWRqiFe", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000114420407032598/v078700_ex10-1.htm", "category_name": "Employment Agreement", "company_name": "Ziopharm Oncology Inc", "created": "June 19th, 2007", "published": true, "pretty": null, "uri": "/contracts/3WaxWRqiFe", "title": "EMPLOYMENT AGREEMENT EXTENSION", "group_id": "3WaxWRqiFe", "group_samples": [{"label": "Employment Agreement (Ziopharm Oncology Inc)", "uri": "/contracts/3WaxWRqiFe", "published": true}], "group_size": 1, "tags": [{"name": "Employment Agreement", "type": "category", "uri": "/contracts/tagged/employment-agreement"}, {"name": "Ziopharm Oncology Inc", "type": "company", "uri": "/company/1107421/ziopharm-oncology-inc"}, {"name": "Services-specialty outpatient facilities, nec", "type": "industry", "uri": "/contracts/tagged/services-specialty-outpatient-facilities-nec"}]}, {"intro": "This is the fourth amendment (\u201cFourth Amendment\u201d) of the agreement by and between the IC and Licensee having an effective date of May 28, 2019 and having IC Reference Number L-190-2019-0 (\u201cAgreement\u201d). This Fourth Amendment, having IC Reference Number L-190-2019-4 includes, in addition to the amendments made below, 1) a Signature Page, 2) Attachment 1 (Royalty Payment Information), and 3) Appendix A - Patent(s) or Patent Application(s).", "id": "3gomI8Txw3C", "source_url": "https://www.sec.gov/Archives/edgar/data/1107421/000095017022004972/tcrt-ex10_39.htm", "category_name": "Amendment Agreement", "company_name": "Alaunos Therapeutics, Inc.", "created": "March 30th, 2022", "published": true, "pretty": null, "uri": "/contracts/3gomI8Txw3C", "title": "CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE ALAUNOS THERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) IS CUSTOMARILY AND ACTUALLY TREATED AS PRIVATE. PUBLIC HEALTH...", "group_id": "3gomI8Txw3C", "group_samples": [{"label": "Amendment Agreement (Alaunos Therapeutics, Inc.)", "uri": "/contracts/3gomI8Txw3C", "published": true}], "group_size": 1, "tags": [{"name": "Amendment Agreement", "type": "category", "uri": "/contracts/tagged/amendment-agreement"}, {"name": "Alaunos Therapeutics, Inc.", "type": "company", "uri": "/company/1107421/alaunos-therapeutics-inc"}, {"name": "Pharmaceutical preparations", "type": "industry", "uri": "/contracts/tagged/pharmaceutical-preparations"}]}], "next_curs": "CjEKEAoKZ3JvdXBfc2l6ZRICCAEKGQoIZ3JvdXBfaWQSDRoLM2dvbUk4VHh3M0MYACAB", "cursor": "CjEKEAoKZ3JvdXBfc2l6ZRICCAMKGQoIZ3JvdXBfaWQSDRoLNXJoMnVaMnFXS0oYACAB"}}